INS and metabolic dysfunction-associated steatohepatitis: For example, for patients with type 2 diabetes, priority could be given to patients at increased risk of morbidity and mortality indicated by poor glycemic control, insulin use, cardiovascular disease, albuminuria, chronic kidney disease, nonalcoholic steatohepatitis, or multiple cardiometabolic comorbidities.